Efficacy and safety of LixiLan, a fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes not adequately controlled on basal insulin: LixiLan-L trial

被引：0
|
作者：
Aroda, V. R. [1 ]
Rosenstock, J. [2 ]
Wysham, C. [3 ]
Unger, J. [4 ]
Bellido, D. [5 ]
Galvez, G. Gonzalez [6 ]
Takami, A. [7 ]
Guo, H. [8 ]
Niemoeller, E. [9 ]
Souhami, E. [10 ]
Bergenstal, R. M. [11 ]
机构：
[1] Medstar Hlth Res Inst, Hyattsville, MD USA
[2] Dallas Diabet & Endocrine Ctr Med City, Dallas, TX USA
[3] Rockwood Clin, Spokane, WA USA
[4] Catalina Res Inst, Chino, CA USA
[5] Complejo Hosp Univ Ferrol, La Coruna, Spain
[6] Inst Jalisci Invest Diabet & Obesidad SC, Guadalajara, Jalisco, Mexico
[7] Sanofi, Tokyo, Japan
[8] BMD Consulting Inc, Somerset, NJ USA
[9] Sanofi, Frankfurt, Germany
[10] Sanofi, Paris, France
[11] Int Diabet Ctr, Minneapolis, MN USA
来源：
DIABETOLOGIA | 2016年 / 59卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4
引用
收藏
页码：S2 / S3
页数：2
相关论文
共 50 条
  • [21] Fixed-Ratio Combination of Insulin and GLP-1 RA in Patients with Longstanding Type 2 Diabetes: A Subanalysis of LixiLan-L
    Lawrence Blonde
    Lori Berard
    Aramesh Saremi
    Yao Huang
    Vanita R. Aroda
    Denis Raccah
    Diabetes Therapy, 2020, 11 : 1007 - 1015
  • [22] Improved glucose control without increased hypoglycaemia risk with insulin glargine/lixisenatide fixed-ratio combination (LixiLan) vs insulin glargine alone
    Berria, R.
    Guerci, B.
    Paranjape, S.
    Souhami, E.
    Aroda, V.
    Rosenstock, J.
    DIABETOLOGIA, 2015, 58 : S55 - S55
  • [23] Efficacy and safety of insulin glargine/lixisenatide (iGlarLixi) fixed-ratio combination in older adults with type 2 diabetes
    Handelsman, Yehuda
    Chovanes, Christina
    Dex, Terry
    Giorgino, Francesco
    Skolnik, Neil
    Souhami, Elisabeth
    Stager, William
    Niemoeller, Elisabeth
    Frias, Juan Pablo
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2019, 33 (03) : 236 - 242
  • [24] Characteristics and Glycemic Outcomes of T2D Patients (Pts) Titrated to 60 U/day with Insulin Glargine/Lixisenatide Fixed-Ratio Combination (iGlarLixi) vs. Insulin in the LixiLan-L Trial
    Blonde, Lawrence
    Bailey, Timothy S.
    Chao, Jason
    Dex, Terry
    Frias, Juan P.
    Meneghini, Luigi F.
    Roberts, Michelle
    Aroda, Vanita R.
    DIABETES, 2017, 66 : A294 - A294
  • [25] Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical Trial
    Watada, Hirotaka
    Takami, Akane
    Spranger, Robert
    Amano, Atsushi
    Hashimoto, Yasuhiro
    Niemoeller, Elisabeth
    DIABETES CARE, 2020, 43 (06) : 1249 - 1257
  • [26] Titratable fixed-ratio vs sequential combination of insulin glargine and lixisenatide in type 2 diabetes uncontrolled on basal insulin
    Meier, J. J.
    Vidal, J.
    Liu, M.
    Perfetti, R.
    Rosenstock, J.
    DIABETOLOGIA, 2017, 60 : S372 - S372
  • [27] Titratable Fixed-Ratio vs. Sequential Combination of Insulin Glargine and Lixisenatide: Propensity Score-Matched Analysis to Compare LixiLan-L and GetGoal Duo-2 Trials
    Meier, Juris J.
    Vidal, Josep
    Liu, Minzhi
    Perfetti, Riccardo
    Rosenstock, Julio
    DIABETES, 2017, 66 : A622 - A623
  • [28] Benefits of a Fixed-Ratio Formulation of Once-Daily Insulin Glargine/Lixisenatide (LixiLan) vs. Glargine in Type 2 Diabetes (T2DM) Inadequately Controlled on Metformin
    Rosenstock, Julio
    Diamant, Michaela
    Silvestre, Louise
    Souhami, Elisabeth
    Zhou, Tianyue
    Fonseca, Vivian
    DIABETES, 2014, 63 : A87 - A88
  • [29] Clinical Impact of Titratable Fixed-Ratio Combination of Insulin Glargine/Lixisenatide vs. Each Component Alone in Type 2 Diabetes Inadequately Controlled on Oral Agents: LixiLan-O Trial
    Rosenstock, Julio
    Aronson, Ronnie
    Hanefeld, Markolf
    Piatti, Piermarco
    Serusclat, Pierre
    Cheng, Xi
    Zhou, Tianyue
    Nie-Moeller, Elisabeth
    Souhami, Elisabeth
    Grunberger, George
    Davies, Melanie
    DIABETES, 2016, 65 : A48 - A49
  • [30] Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial
    Wysham, Carol
    Bonadonna, Riccardo C.
    Aroda, Vanita R.
    Puig Domingo, Manuel
    Kapitza, Christoph
    Stager, William
    Yu, Christine
    Niemoeller, Elisabeth
    Souhami, Elisabeth
    Bergenstal, Richard M.
    DIABETES OBESITY & METABOLISM, 2017, 19 (10): : 1408 - 1415
12345